m+Medelevator.RU
← Поиск публикаций
Acute and critical care · 2021

Atrial fibrillation of new onset during acute illness: prevalence of, and risk factors for, persistence after hospital discharge.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Ramanathan Abarna, Pearl John Paul, Li Manshi, Wang Xiaofeng, Sadana Divyajot, Duggal Abhijit

Аннотация

BACKGROUND: Atrial fibrillation (AF) of new onset during acute illness (AFNOAI) has a variable incidence of 1%-44% in hospitalized patients. This study assesses the risk factors for persistence of AFNOAI in the 5 years after hospital discharge for critically ill patients.

METHODS: This was a retrospective cohort study. All patients ≥18 years old admitted to the medical intensive care unit (MICU) of a tertiary care hospital from January 1, 2012, to October 31, 2015, were screened. Those designated with AF for the first time during the hospital admission were included. Risk factors for persistent AFNOAI were assessed using a Cox's proportional hazards model.

RESULTS: Two-hundred and fifty-one (1.8%) of 13,983 unique MICU admissions had AFNOAI. After exclusions, 108 patients remained. Forty-one patients (38%) had persistence of AFNOAI. Age (hazard ratio [HR], 1.05; 95% confidence interval [CI], 1.01-1.08), hyperlipidemia (HR, 2.27; 95% CI, 1.02-5.05) and immunosuppression (HR, 2.29; 95% CI, 1.02-5.16) were associated with AFNOAI persistence. Diastolic dysfunction (HR, 1.46; 95% CI, 0.71-3.00) and mitral regurgitation (HR, 2.00; 95% CI, 0.91-4.37) also showed a trend towards association with AFNOAI persistence.

CONCLUSIONS: Our study showed that AFNOAI has a high rate of persistence after discharge and that certain comorbid and cardiac factors may increase the risk of persistence. Anticoagulation should be considered, based on a patient's individual AFNOAI persistence risk.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты